Results 171 to 180 of about 337,623 (298)
Iterative Spectral Mollification and Conjugation for Successive Edge Detection [PDF]
Robert E. Tuzun, Jae-Hun Jung
openalex +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Enhancing conjugation from E. coli to Streptomyces coelicolor by incorporating traJ into mobilizable plasmids. [PDF]
Valdés-Chiara P +4 more
europepmc +1 more source
Conjugation of nanomaterials containing rare-earth ion Tb3+ with CD133 monoclonal antibody and its potentials for labeling colon cancer cells (HT-29) [PDF]
Le Nhat Minh +5 more
openalex +1 more source
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Double-hit approach for novel glycoconjugates combining cytoplasmic glycoengineering and selective chemistry. [PDF]
Palmieri E +5 more
europepmc +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source

